Departments of 1Oncology, Vejle Hospital, Vejle, Denmark.
Anticancer Res. 2012 Sep;32(9):3817-25.
New biological markers with predictive or prognostic value are highly warranted in the treatment of ovarian cancer. The platelet-derived growth factor (PDGF) system and fibroblast growth factor (FGF) system are important components in tumor growth and angiogenesis.
Pre-surgery peripheral blood samples were collected consecutively from 213 patients (42 with normal ovaries, 54 with benign, 21 with borderline, and 96 with malignant ovarian tumors) undergoing surgery for an untreated pelvic mass. Serum PDGF-AA, PDGF-BB, and FGF2 were quantified on a Luminex analyzer.
Median PDGF-AA, PDGF-BB, and FGF2 levels were higher in patients with ovarian cancer than in those with borderline tumors, and normal ovaries, and PDGF-BB and FGF2 were also higher as compared to patients with benign tumors. PDGF-AA and PDGF-BB were associated with FIGO stage and residual tumor and PDGF-BB was associated with histological subtype.
PDGF-AA, PDGF-BB, and FGF2 are up-regulated in ovarian cancer and levels of serum PDGF-AA and PDGF-BB seem to be associated with stage and residual tumor in ovarian cancer.
在卵巢癌的治疗中，非常需要具有预测或预后价值的新生物标志物。血小板衍生生长因子（PDGF）系统和成纤维细胞生长因子（FGF）系统是肿瘤生长和血管生成的重要组成部分。
连续采集了 213 名接受手术治疗未治疗性盆腔肿块的患者（42 名正常卵巢、54 名良性、21 名交界性和 96 名恶性卵巢肿瘤）术前外周血样本。使用 Luminex 分析仪定量测定血清 PDGF-AA、PDGF-BB 和 FGF2。
卵巢癌患者的 PDGF-AA、PDGF-BB 和 FGF2 中位数水平高于交界性肿瘤和正常卵巢患者，PDGF-BB 和 FGF2 也高于良性肿瘤患者。PDGF-AA 和 PDGF-BB 与 FIGO 分期和残留肿瘤有关，PDGF-BB 与组织学亚型有关。
PDGF-AA、PDGF-BB 和 FGF2 在卵巢癌中上调，血清 PDGF-AA 和 PDGF-BB 的水平似乎与卵巢癌的分期和残留肿瘤有关。
